Andres F. Martinez ☢☢

⚕| Médico

☢| Radiation Oncologist (UBA)🇦🇷

🩺| Medical Auditor (UPC)

#Radiotherapy
#Radiooncology
#Radiocirugia
#Radonc

🌎 Colombia 🇨🇴

[Andres F. Martinez ☢☢ @AndresFMC_RT]

@defensoresco ADLE 👍💪🙏

[Luis Moreno Sánchez @radioncoluis]

Guiding Treatment for Patients With Prostate Cancer With Biochemical Recurrence After Prostatectomy

Guía de tratamiento para pacientes con cáncer de próstata con recurrencia bioquímica tras prostatectomía

https://t.co/pAnn9WYcn1

[Nicholas Zaorsky, MD MS @NicholasZaorsky]

Guiding Treatment for Patients With Prostate Cancer With Biochemical Recurrence After Prostatectomy
https://t.co/2TF9uZEFk7
with @AmarUKishan @DrSpratticus

Thanks @ASCO Daily News

Related @NatRevUrol article: https://t.co/AFzrHLoEYW
https://t.co/kfBMkjK6lD

[Gustavo @gusviani]

🎙️Can we revolutionize glottic cancer treatment in just 3 fractions? 🤔 @OncoAlert
🎯 Objective
Evaluate the safety and efficacy of SBRT (36 Gy/3 fractions) for T1 glottic cancer
🛠️ Methods
•Design: Prospective phase I/II study, 33 👥
•Treatment: Affected cords received 36 Gy; adjacent areas, 30 Gy
•Endpoints: Local control, toxicity, and voice quality.
📊 Outcomes
•Local control: 100% at 4 y😱
•Toxicity: 24% developed late grade ≥3 toxicity, including necrosis🥶
•Voice Quality: Improved by 6 mo post-treatment🤞
🏁 Conclusion
SBRT offers excellent control but late toxicity (especially in smokers) is a concern. Dose ⬇️ and 👥 selection are key❗️

[Pervin Hurmuz @PervinHurmuz]

Take a look at our new article where we evaluated and compared our prostate cancer SBRT treatment protocols! 🙏🤗@mtugceyilmaz https://t.co/ayBwXaFGXN

[Gustavo @gusviani]

🚨 PSMA-PET in Biochemically Recurrent Prostate Cancer: A Paradigm Shift❗️
✔️Recent findings reveal that PSMA-PET/CT detects M1 metastatic disease in 46% of 👥 previously classified as non-metastatic by conventional imaging. This study sheds light on the limitations of traditional staging in high-risk, hormone-sensitive prostate cancer⚠️
📊 Key Findings:
•84% PSMA-PET ➕: Across 👥 w/ biochemical recurrence
•46% detected M1 disease: A substantial rate of under-staged metastases
•Polymetastatic disease (>5 lesions): Found in 24% of cases😱
🔍 Implications:
Conventional imaging underestimates disease burden, potentially altering treatment plans. PSMA-PET offers ⬆️accuracy for staging and risk stratification, guiding interventions like MDT and systemic treatment

[Gustavo @gusviani]

🧵 SBRT in Oligometastatic Breast Cancer: What does the evidence show? A summary of key studies and their impact on survival. Let’s dive in! 👇

1/ What is Oligometastatic Breast Cancer (OMBC)?
OMBC is an intermediate state between localized and widespread metastatic disease, characterized by limited metastases (typically ≤5). It’s a promising target for local therapies like SBRT (Stereotactic Body Radiotherapy).

[Gustavo @gusviani]

🎙 2 CTH cycles less do not compromise the results w/ a ⬆️ CR-R 🟰RAPIDO trial ❗️@OncoAlert @TheLancetOncol
📌Methods
* 👥: high-risk locally advanced #rectalcancer (LARC).
* Study design: Prospective observational cohort study.
* Treatment: Short-course ☢️➡️4 CAPOX or 6 FOLFOX➡️mesorectal excision or watch-and-wait (W&W) for clinical complete response (cCR).
* 🎯: Complete response (CR), locoregional recurrences, neurotoxicity.
📊Outcomes
* CR rate: 🟰RAPIDO trial (24%)
* LRR: ⬇️⬇️(around 5-6%)
* Neurotoxicity: ⬇️than RAPIDO trial
https://t.co/5h5A8emXBs

[Andres F. Martinez ☢☢ @AndresFMC_RT]

Ya brindamos a toda la población de córdoba y la región caribe de Colombia 🇨🇴, servicios de radioterapia de Altas Tecnologias como Radiocx (SRS) y SBRT, uso Halcyon y velocity para mayor precisión y calidad de tratamientos. ☢
#Radonc
#IMATOncomedicaAUNA
#Innovación
#Tecnología

[Andres F. Martinez ☢☢ @AndresFMC_RT]

Ya contamos en IMAT Oncomedica AUNA, Monteria (Cordoba) 🇨🇴, la posibilidad de ofrecer a nuestros pacientes oncologicos adultos y pediátricos, tratamientos de radioterapia de Altas tecnologias como Radiocirugia Intracraneal (SRS) y SBRT con un Halcyon actualizado y uso de Velocity

[JAMA Oncology @JAMAOnc]

This Special Communication discusses case-referenced consensus and evidence-based guidelines to inform clinical practice in unresectable locally advanced NSCLC. https://t.co/kh2WiHSz0N

[Luis Moreno Sánchez @radioncoluis]

Target Delineation in Postoperative Radiation Therapy for Head and Neck Cancer After Flap Reconstruction.
https://t.co/V3bcFuojbE

[Gustavo @gusviani]

🎙 Promising OS and safety outcomes of SBRT before DDLT for unresectable #HCC❗️@OncoAlert @JAMANetworkOpen
📌Study Design:
•Ph 2 nonRCT
•32 👥 w/unresectable HCC
Intervention:
•SBRT ➡️ 35 to 50 Gy/5 fx
•SBRT as bridging deceased donor liver transplant (DDLT) for matching graft availability
📊RESuLTs
•Median PFS:17.6 m
•Median OS: 60.5 m
•5-y PFS /OS: 39.9%/51.3%
◦RECIST 1.1: 75.0%
◦mRECIST: 83.9%
◦PERCIST: 87.5% (by lesions)
•PCR: 75.0% of 👥 and 58.3% of lesions for who underwent DDLT
•AEs: 1 G3 event
doi:10.1001/jamanetworkopen.2024.15998

[Luis Moreno Sánchez @radioncoluis]

Impact of radiation therapy for breast cancer with involved surgical margin after immediate breast reconstruction: A multi-institutional observational study.

https://t.co/vHEC4ilyiv

[Gustavo @gusviani]

🎙 IMRT re☢️ and nivolumab suggested a promising ⬆️ in PFS over historical controls @OncoAlert @JAMAOnc
📌DESIGN
Ph2 investigated nivolumab combined w/ re-IMRT for recurrent/second primary #HNSCC
➖51 👥 received 60-66 Gy IMRT w/ nivolumab before, during and after ☢️➡️nivolumab alone for up to 1 y
➖🎯PFS ⬆️Miri study (43.8%)
📊RESULTS
➖After a median FU 24.5 m
➖1y PFS 61.7% vs 43.8%Hcontrol
➖Re☢️was well-tolerated w/ fatigue and lymphopenia as the most common AES
https://t.co/fHTbRmxfut

[Luis Moreno Sánchez @radioncoluis]

EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer—2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent.

https://t.co/aedtedpn0q

EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer.
Part II: 2024 Update - Treatment of Relapsing and Metastatic Prostate Cancer.

https://t.co/YRX2d7ts4F

[Priyamvada Maitre @docpriyamvada]

🚨Our NEW paper out from POP-RT trial @VedangMurthy in @IJROBP !!!🤩

Elective pelvic #radiotherapy in HR-VHR #prostatecancer ⬆️ ⬆️BFFS, DFS, MFS

Does toxicity REALLY increase⁉️
Short: NO
Long: ~10% higher gr2 late urinary (p=NS)
1/

https://t.co/wCJud1EVGw

[Gustavo @gusviani]

🎙️Neoadjuvant CHT followed by 🔪failed in demonstrating ⬆️ OS ✖️ CCRT for IB2-IIb #cervicalcarcinoma‼️@OncoAlert @ASCO
📌Ph3 RCT comparing neoadjuvant chemotherapy + 🔪 (NACT-S)✖️standard CCRT
- 626 👥 w/ stage IB2-IIb cervical carcinoma
-🥇🎯 : 5-y OS
📊RESULTs
- 31.6% ⚰️ after 8.7 y median FU
- Balanced age, stage, cell type in both arms
- Completion of protocol: 71% in NACT-S, 82% in CCRT
- Additional interventions: RT post NACT-S (48%), 🔪 post CCRT (8%)
- Short-term AEs ≥G3 + in NACT-S (41% vs. 23%), long-term AEs ≥ G3 ⬆️ in CCRT (21% vs. 15%)
- 5-y OS not significantly different: NACT-S (72%)✖️CCRT (76%)
https://t.co/HhKql1Rn8U

[Felipe Couñago PhD @fcounago]

📄 “LA SBRT ES UNA NUEVA OPCIÓN DE TRATAMIENTO EN EL CÁNCER RENAL “ . Nuestra Editorial ha sido publicada en @actasurologicas 🔥

✅ La #SBRT está indicada en pacientes estadio I-III inoperables

✅ Además, debe ser considerada en pacientes oligomtx

https://t.co/yU07zFWn3I

[Rohit Malde @roxboxfix]

SABR for HCC
SABR is superior to Sorafenib ( Medan OS = 17m Vs 9.6 m)
Dose 40-50Gy /3-5#
SABR = RFA
1 yr OS = 70-80%
2 yr OS = 40-50%

Largest Metaanalysis
1/2/3 yr OS = 72% / 58% / 48%

1/2/3 yr LC = 86%/83% /83%

Toxicity
GI Gr3 or more= 3.9%
Hepatic Gr3 Or more = 4.7%